timothy sykes logo
KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street Thumbnail
G Google News

KOD Stock Explodes As Zenkuda Trial Data Rewire Wall Street

JACK KELLOGG•UPDATED OCT. 19, 2026, 4:47 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Kodiak Sciences Inc stocks have been trading up by 7.91 percent after promising trial data boosted optimism for its eye drug

Key Takeaways Traders Need To Know

  • Kodiak Sciences reported its Phase 3 DAYBREAK trial in wet age‑related macular degeneration met primary endpoints for Zenkuda and tabirafusp‑ted, with non‑inferior vision gains, strong durability, and favorable safety, and plans 4Q2026 regulatory submissions.
  • Shares of KOD ripped between roughly 100% and nearly 190% intraday after the Phase 3 wet AMD readout, with over half of trial patients holding a six‑month dosing interval.
  • Major firms including LifeSci Capital, Jefferies, H.C. Wainwright, UBS, and Goldman Sachs sharply raised price targets on Kodiak Sciences, some more than doubling them after the DAYBREAK data.
  • H.C. Wainwright flagged that both reformulated Zenkuda and KSI‑501 hit one‑year endpoints versus aflibercept, with strong retinal drying and durability in treatment‑naive wet AMD.
  • Evercore ISI labeled the DAYBREAK press release “excellent” and reiterated an Outperform rating as KOD spiked about 156% intraday despite broader market weakness.

Candlestick Chart

Live Update At 16:46:57 EDT: On Monday, October 19, 2026 Kodiak Sciences Inc stock [NASDAQ: KOD] is trending up by 7.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Kodiak Sciences Inc (KOD) has gone from quiet biotech to momentum magnet. The DAYBREAK data in late September triggered a violent rerating: the stock launched from the low $30s on 2026/09/25 to close near $90 just three sessions later. That is the kind of move that pulls every short‑term trader into the chart.

Since then, KOD has been consolidating. Daily closes have chopped mostly between $85 and $100, with recent action around $91. On the intraday 5‑minute chart, KOD shows tight, controlled trading between roughly $88 and $93, with repeated support near $90 and resistance around $92.75. That price action screams digestion after a news‑driven squeeze.

More Breaking News

Under the hood, Kodiak Sciences is still a classic development‑stage biotech. The latest quarter shows negative EBITDA of about $59.5M and a net loss of roughly $65.6M, with no listed revenue yet. Cash and equivalents around $125.9M and working capital near $78.6M give KOD some runway, but returns on equity and assets are deeply negative. For traders, that means the story is almost entirely about data, approvals, and future sales — not current profits.

Why Traders Are Watching KOD After The DAYBREAK Shock

KOD is on every momentum watchlist because the catalyst is clean and huge. Kodiak Sciences told the market its pivotal Phase 3 DAYBREAK trial in wet age‑related macular degeneration hit primary endpoints for both Zenkuda and tabirafusp‑ted. Vision gains were non‑inferior to aflibercept, a leading standard of care, but durability was stronger and safety looked favorable. For biotech trading, that is a textbook de‑risking event.

The market reaction shows exactly how dramatic that shift was. Reports highlight KOD shares more than doubling, with surges quoted from over 99% to nearly 190% intraday as traders stampeded into the name. That kind of move usually only comes when sentiment flips from “maybe this works” to “this probably becomes a real product.”

Durability is the other key piece. Kodiak Sciences said over half of patients could stay on a six‑month dosing interval while holding vision outcomes similar to aflibercept. For a chronic eye disease that needs frequent injections, fewer shots are a major selling point. Traders who understand that angle see why analysts are now modeling higher peak sales for Zenkuda.

Wall Street’s reaction backs up the tape. LifeSci Capital lifted its KOD target to $145 from $85, Jefferies doubled its target to $112, and H.C. Wainwright pushed from $58 to $96 after calling out strong retinal drying and durability for both Zenkuda and KSI‑501. UBS went from $80 to $120, pointing to a Q4 BLA filing and a potential 2027 launch, while Goldman Sachs hiked from $36 to $103 but stayed Neutral, reminding traders that valuation risk is real after a near‑tripling. For active traders, KOD is now a high‑beta biotech with clear catalysts and a broadening late‑stage retina portfolio, not just a one‑drug lotto ticket.

Conclusion

For Kodiak Sciences and KOD, the DAYBREAK readout is more than a one‑day headline. The company is now talking about regulatory submissions for Zenkuda in multiple retinal indications in 2026/10, backed by five positive Phase 3 studies across wet AMD, diabetic retinopathy, and retinal vein occlusion. At the same time, Kodiak is advancing tabirafusp‑ted in a Phase 3 DME program and KSI‑101 in another Phase 3 trial, setting up a potential two‑drug commercial story by 2027/2028.

The flip side is that Kodiak Sciences is still burning cash, posting quarterly operating cash outflows over $46M and no current revenue. Valuation metrics like a price‑to‑book ratio above 100 show how heavily KOD trades on future expectations. That is why some firms, like Goldman Sachs, raised targets aggressively yet stayed Neutral — a signal that a lot of good news may already be in the price.

For traders, this is where discipline matters. KOD now trades like a classic post‑catalyst runner: huge gap, tight consolidation, and a crowded watchlist. As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. Breaks above the recent $95–$100 zone can trigger fresh momentum, while a crack of the $85 area may signal profit‑taking and a deeper unwind. As Tim Sykes likes to say, “Big news and big moves are great, but the only way to stay in this game is to cut losses quickly and never marry a stock.” This article is for educational and research purposes only, but the lesson for KOD is clear: respect the volatility, trade the levels, and let the chart confirm the story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”